Biohaven Ltd. (BHVN) Form 10-Q — May 4, 2026
Biohaven Ltd. reported a net loss of $130.5 million, or $0.88 per share, for the quarter ended March 31, 2026, compared to a net loss of $221.7 million, or $2.17 per share, in the prior-year period. The reduction in net loss was primarily driven by decreased research and development expenses, which fell to $103.8 million from $187.6 million, and lower general and administrative expenses, following a strategic reprioritization of development programs initiated in late 2025. The company significantly strengthened its balance sheet during the quarter, raising approximately $178.9 million in net proceeds through the sale of 17.2 million common shares under its Equity Distribution Agreement.
Key figures
- Shares Outstanding
- 150560990
- General And Administrative Expenses
- 26601000
Price after filing
Close on the filing date to close N calendar days later (from $10.14). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.